VRNA — Verona Pharma Income Statement
0.000.00%
Last trade - 00:00
- $2.41bn
- $2.13bn
- 34
- 15
- 88
- 42
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 40 | 0.458 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0.112 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 52.4 | 74.3 | 113 | 77 | 67.6 |
Operating Profit | -52.4 | -74.3 | -73.3 | -76.6 | -67.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -40.5 | -65 | -55.6 | -68.4 | -53.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -40.6 | -65.1 | -55.6 | -68.7 | -54.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -40.6 | -65.1 | -55.6 | -68.7 | -54.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -40.6 | -65.1 | -55.6 | -68.7 | -54.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.39 | -0.25 | -0.117 | -0.129 | -0.086 |